Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
We examined the effect of intravenously infused glucagon-like peptide 1 (GLP-1) on subjective appetite sensations after an energy-fixed breakfast, and on spontaneous energy intake at an ad libitum lunch. 20 young, healthy, normal-weight men participated in a placebo-controlled, randomized, blinded, crossover study. Infusion (GLP-1, 50 pmol/ kg.h or saline) was started simultaneously with initiation of the test meals. Visual analogue scales were used to assess appetite sensations throughout the experiment and the palatability of the test meals. Blood was sampled throughout the day for analysis of plasma hormone and substrate levels. After the energy-fixed breakfast, GLP-1 infusion enhanced satiety and fullness compared with placebo (treatment effect: P < 0.03). Furthermore, spontaneous energy intake at the ad libitum lunch was reduced by 12% by GLP-1 infusion compared with saline (P = 0.002). Plasma GLP-1, insulin, glucagon, and blood glucose profiles were affected significantly by the treatment (P < 0.002). In conclusion, the results show that GLP-1 enhanced satiety and reduced energy intake and thus may play a physiological regulatory role in controlling appetite and energy intake in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 RA increase satiety, reduce food intake and delay gastric emptying whilst they also stimulate insulin release and inhibit glucagon secretion in a glucose-dependent manner (Fig. 1) [17, 18].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Short-term studies have demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RA) induce weight loss by promoting satiety and reducing hunger16–19.”
From Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, non-clinical and clinical studies have demonstrated increased satiety, reduced food intake and subsequent reductions in body weight following administration of GLP-1,7, 8”
From Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults (2014) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among the two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the latter has been established as having therapeutic potential for reducing elevated plasma glucose (1, 2) and body weight (3), while the former has been unable to either stimulate insulin secretion (1) or lower plasma glucose effectively in type 2 diabetes (T2D) (4).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [3]
In the citing paper
“GLP-1 receptor agonists (GLP-1RA) have been shown to promote weight loss and decrease liver fat [28,29] (Figure 1).”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [29]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1975) · Journal of AOAC INTERNATIONAL · doi:10.1093/jaoac/58.5.1085 · Cited by 19,795
(1974) · Elsevier eBooks · doi:10.1016/b978-0-12-091304-6.x5001-0 · Cited by 6,755
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citationTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationInduction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Self-citationScrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Cited by
Items 701–800 of 1,003
New advances in models and strategies for developing anti-obesity drugs
Kim, G. W., Lin, J. E., Blomain, E. S., & Waldman, S. A. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.792804 · Cited by 37
“Administration of GLP-1 in animals and humans induces satiety and weight loss [94-97].”
BackgroundJiang, J., Zhang, J., Jacobsen, L. V., & Hu, P. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010389468 · Cited by 28
“Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.”
BackgroundExendin-4, a GLP-1 Receptor Agonist, Modulates the Effect of Macronutrients on Food Intake by Rats
Aziz, A. A., & Anderson, G. H. (2002) · Journal of Nutrition · doi:10.1093/jn/132.5.990 · Cited by 32
Heni, M., Kullmann, S., Gallwitz, B., Häring, H., Preissl, H. T., & Fritsche, A. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.09.007 · Cited by 33
“Since, this effect on eating behavior is not limited to specific drugs, it can also be induced by native GLP-1 administration [5,6].”
BackgroundInvestigational therapies in the treatment of obesity
Mancini, M. C., & Halpern, A. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.8.897 · Cited by 31
“Infusions of supraphysiological amounts of GLP-1 significantly enhance satiety and reduce feeding in normal subjects [119,120].”
BackgroundEffects of a Preload on Reduction of Food Intake by GLP-1 in Healthy Subjects
Degen, L. P., Oesch, S., Matzinger, D., Drewe, J., Knupp, M., Zimmerli, F., & Beglinger, C. (2006) · Digestion · doi:10.1159/000097585 · Cited by 29
“This feedback loop inhibits upper gastrointestinal digestive functions (gastric acid secretion, gastric emptying, exocrine pancreatic secretion), but also affects appetite and food ingestion [”
Neuroendocrine Peptides of the Gut and Their Role in the Regulation of Food Intake
Schalla, M. A., Taché, Y., & Stengel, A. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200007 · Cited by 30
Yamanouchi, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010027 · Cited by 40
“This led to a highly successful class of drugs—GLP-1 receptor agonists (GLP-1RAs)—that established a new benchmark for metabolic therapy, creating a high bar for any subsequent innovations [5].”
Gejl, M., Rungby, J., Brock, B., & Gjedde, A. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12240 · Cited by 27
Incretin-based therapies: can we achieve glycemic control and cardioprotection?
Angeli, F. S., & Shannon, R. P. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0195 · Cited by 30
“Incretins and CV effects of weight loss GLP-1R activation in the hypothalamus reduces appetite and promotes satiety by inhibition of gastric emptying, leading to weight loss (Flint et al. 1998, Larsen et al. 2001).”
BackgroundExendin(9‐39) NH 2 : Recommendations for clinical use based on a systematic literature review
Gasbjerg, L. S., Bari, E. J., Christensen, M., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14507 · Cited by 29
Mechanisms for the cardiovascular effects of glucagon-like peptide-1
Poudyal, H. (2015) · Acta Physiologica · doi:10.1111/apha.12604 · Cited by 34
“In healthy, diabetic and obese humans, peripheral administration of GLP-1 and exenatide, a long-acting GLP-1 agonist, promotes satiety, decreases energy intake and induces weight loss in overweight or obese patients with or without type 2 diabetes (Flint et al. 1998, Vilsboll et al. 2012).”
BackgroundEating disorders and gastrointestinal peptides
Tong, J., & D’Alessio, D. D. (2011) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328341e12b · Cited by 27
Li, W.-X., Gou, J.-F., Tian, J.-H., Yan, X., & Yang, L. (2010) · Current Therapeutic Research · doi:10.1016/j.curtheres.2010.08.003 · Cited by 27
Emerging GLP-1 receptor agonists
Lund, A., Knop, F. K., & Vilsbøll, T. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.616493 · Cited by 26
“Additionally, GLP-1 decreases gastrointestinal motility [14] and promotes satiety [15], probably through activation of GLP-1Rs in the brain in combination with GLP-1-induced decrease in gastric emptying.”
BackgroundBakhøj, S., Flint, A., Holst, J. J., & Tetens, I. (2003) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1601680 · Cited by 29
Self-citationTipping the Balance: the Pathophysiology of Obesity and Type 2 Diabetes Mellitus
McKenney, R., & Short, D. K. (2011) · Surgical Clinics of North America · doi:10.1016/j.suc.2011.08.007 · Cited by 33
Acute sleep deprivation delays the glucagon-like peptide 1 peak response to breakfast in healthy men
Benedict, C., Barclay, J. L., Ott, V., Oster, H., & Hallschmid, M. (2013) · Nutrition and Diabetes · doi:10.1038/nutd.2013.20 · Cited by 29
Gastrointestinal peptides controlling body weight homeostasis
Zerón, H. M., López, M., & Diéguez, C. (2007) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2007.11.009 · Cited by 36
O'Harte, F. P. M., Mooney, M., Kelly, C., McKillop, A. M., & Flatt, P. R. (2001) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00125-7 · Cited by 27
Obesity: an epidemic in need of therapeutics
der Ploeg, L. H. T. V. (2000) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00114-9 · Cited by 28
Glucagon-like peptide-1: physiology and therapeutic potential
Holst, J. J. (2005) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000151395.52819.47 · Cited by 30
Self-citationBray, G. A. (2005) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2004.09.009 · Cited by 29
Gutniak, M. K., Svartberg, J., Hellström, P. M., Holst, J. J., Adner, N., & Ahrén, B. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00862.x · Cited by 27
Self-citationGLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action
Burcelin, R., Gourdy, P., & Dalle, S. (2014) · Physiology · doi:10.1152/physiol.00009.2013 · Cited by 26
The (dys)regulation of energy storage in obesity
Levin, B. E., Geary, N., & Lutz, T. A. (2025) · Physiological Reviews · doi:10.1152/physrev.00002.2024 · Cited by 29
The gut sensor as regulator of body weight
Reinehr, T., & Roth, C. L. (2014) · Endocrine · doi:10.1007/s12020-014-0518-1 · Cited by 30
“Peripheral GLP-1 administration in humans enhances the sensation of satiety and reduces food intake [39].”
Kokkinos, A. D., Tsilingiris, D., le Roux, C. W., Rubino, F., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.153960 · Cited by 29
Foghsgaard, S., Vedtofte, L., Andersen, E. S., Bahne, E., Andreasen, C. H., Sørensen, A. L., Forman, J. L., Mathiesen, E. R., Svare, J., Clausen, T. D., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15306 · Cited by 28
“21,22,49 Our findings are in agreement with previous reports observed in patients with type 2 diabetes 49 – 51 and in obese individuals with or without prediabetes (3.0 mg liraglutide).”
ResultInfluentialSelf-citationGlucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes
Ottney, A. R. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp130081 · Cited by 27
Ghrelin, GLP-1, and leptin responses during exposure to moderate hypoxia
Morishima, T., & Goto, K. (2015) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2015-0311 · Cited by 26
“appetite regulation (Flint et al. 1998; Shintani et al. 2001; Wren et al. 2001).”
Prevention and Treatment of Type 2 Diabetes: A Pathophysiological-Based Approach
Samocha‐Bonet, D., Debs, S. R., & Greenfield, J. R. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.03.014 · Cited by 29
Green, B., Gault, V. A., Irwin, N., Mooney, M. H., Bailey, C. J., Harriott, P., Greer, B., Flatt, P. R., & O'Harte, F. P. M. (2003) · Biological Chemistry · doi:10.1515/bc.2003.171 · Cited by 28
“Third, GLP-1 appears to suppress food intake and may exert insulin-like actions on muscle and other extrapancreatic tissues (Flint et al., 1998; Valverde 2002).”
BackgroundOn the Treatment of Diabetes Mellitus with Glucagon‐like Peptide‐1
Holst, J. J., Deacon, C. F., TOFT‐NIELSEN, M., & Knudsen, L. B. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb11193.x · Cited by 29
Self-citationLi, J., Kuick, R. D., Thompson, R. C., Misek, D. E., Lai, Y. ‐., Yun-Qiang, L. I. U., Chai, B.-X., Hanash, S., & Gantz, I. (2005) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2005.01317.x · Cited by 29
Becetti, I., Bwenyi, E. L., de Araújo, I. E., Ard, J. D., Cryan, J. F., Farooqi, I. S., Ferrario, C. R., Gluck, M. E., Holsen, L. M., Kenny, P. J., et al. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.05.003 · Cited by 29
Kim, J., Kim, J., Choi, C., Bae, J., & Choi, H. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01497-y · Cited by 26
“GLP-1R plays a pivotal role in glucose homeostasis by enhancing glucose-dependent insulin secretion 135 , suppressing glucagon release 136 and promoting satiety 137,138 .”
Dubé, M., D'Amours, M., & Weisnagel, S. J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14050 · Cited by 25
Kjølbæk, L., Schmidt, J. M., Rouy, E., Jensen, K. J., Astrup, A. V., Bertram, H. C., Hammershøj, M., & Raben, A. (2021) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqab220 · Cited by 26
Self-citationJindal, A., Brietzke, S., & Sowers, J. R. (2012) · Cardiorenal Medicine · doi:10.1159/000343803 · Cited by 28
Gastrointestinal peptides in eating-related disorders
Smith, K., & Moran, T. H. (2021) · Physiology & Behavior · doi:10.1016/j.physbeh.2021.113456 · Cited by 28
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
Cooper, M. E., & van Raalte, D. H. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194749 · Cited by 24
“GLP-1 also plays a key role in the regulation of body weight via various well-characterized mechanisms, including delayed gastric emptying and intestinal transit, and actions in the central nervous system that reduce appetite by stimulating satiety, in particular related to hedonic feeding (6, 7).”
Mize, D. L. E., & Salehi, M. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0377-9 · Cited by 24
Plamboeck, A., Veedfald, S., Deacon, C. F., Hartmann, B., Vilsbøll, T., Knop, F. K., & Holst, J. J. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00123.2015 · Cited by 25
“It has several effects, including augmentation of glucose-stimulated insulin secretion (insulinotropic effect) (40), inhibition of glucagon secretion (glucagonostatic effect) (40), delay of gastric emptying (52), and suppression of appetite and food intake (11).”
BackgroundSelf-citationPhysiometabolic effects of Agave salmiana fructans evaluated in Wistar rats
Andrade, A. I. C., Rivera-Bautista, C., Godínez-Hernández, C. I., Ruiz‐Cabrera, M. A., Ahumada, C. F., Chávez, E. G., & Grajales‐Lagunes, A. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.11.043 · Cited by 25
Upregulation of the brainstem preproglucagon system in the obese Zucker rat
Vrang, N., Larsen, P. J., Jensen, P. B., Lykkegaard, K., Artmann, A., Larsen, L. K., & Tang‐Christensen, M. (2007) · Brain Research · doi:10.1016/j.brainres.2007.10.026 · Cited by 32
Exenatide Use in the Management of Metabolic Syndrome: A Retrospective Database Study
Bhushan, R., Elkind-Hirsch, K. E., Bhushan, M., Butler, W. J., Duncan, K., & Marrioneaux, O. (2008) · Endocrine Practice · doi:10.4158/ep.14.8.993 · Cited by 24
Neuropharmacology of human appetite expression
Halford, J. C. G., & Harrold, J. A. (2008) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.20 · Cited by 24
Holst, J. J. (2021) · Diabetes · doi:10.2337/dbi21-0026 · Cited by 23
“Infusions of GLP-1 were demonstrated to inhibit appetite and food intake in humans in 1998 (63), and the first GLP-1RA (liraglutide) was approved for treatment of obesity in 2013.”
BackgroundSelf-citationYanai, H. (2012) · Journal of Clinical Medicine Research · doi:10.4021/jocmr975w · Cited by 25
“Increases in GLP-1 concentration have been reported to increase satiety [23, 24], which could induce a decrease in food intake following DPP-4 inhibitors treatment.”
BackgroundLiraglutide in the treatment of obesity
Ng, S. Y. A., & Wilding, J. P. H. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.925870 · Cited by 27
“GLP-1 also binds to receptors in the brainstem, hypothalamus and amygdala, where it is thought to promote satiety, leading to decreased energy intake [16-19].”
BackgroundYang, Q., Huang, G., Tian, Q., Liu, W., Sun, X., Li, N., Sun, S., Zhou, T., Wu, N., Wei, Y., et al. (2018) · Medicine · doi:10.1097/md.0000000000009943 · Cited by 28
Li, P., Zhu, L., Yang, X., Li, W., Sun, X., Yi, B., & Zhu, S. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27940 · Cited by 25
Janus, C., Vistisen, D., Amadid, H., Witte, D. R., Lauritzen, T., Brage, S., Bjerregaard, A., Hansen, T. F., Holst, J. J., Jørgensen, M. E., et al. (2019) · Endocrine Connections · doi:10.1530/ec-19-0408 · Cited by 24
Self-citationMiholic, J., Hoffmann, M., Holst, J. J., Lenglinger, J., Mittlböck, M., Bergmann, H., & Stacher, G. (2007) · Surgical Endoscopy · doi:10.1007/s00464-005-0804-3 · Cited by 23
“GLP-1 and PYY also attenuate appetite and lower energy intake in humans [8].”
BackgroundSelf-citationThe spectrum of antidiabetic actions of GLP-1 in patients with diabetes
Vilsbøll, T., Holst, J. J., & Knop, F. K. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.011 · Cited by 25
Self-citationA model for the dynamics of human weight cycling
Goldbeter, A. (2006) · Journal of Biosciences · doi:10.1007/bf02705242 · Cited by 23
“The second term in eq. (1b) –besides reflecting negative regulation by cognitive restraint R– expresses the effect of other gastrointestinal peptides such as cholecystokinin and glucagon-like peptide-1, which promote satiety and reduce food intake in humans ( Flint et al 1998; Woods 2004).”
BackgroundYamanouchi, D. (2025) · doi:10.20944/preprints202511.1408.v2 · Cited by 23
Mersebach, H., Svendsen, O. L., Holst, J. J., Astrup, A., & Feldt‐Rasmussen, U. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01675.x · Cited by 22
Self-citationLi, Y., Fan, Q., Pang, R., Cai, L., Qi, J., Chen, W., Zhang, Y., Chen, C., Yu, W., & Li, P. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03465-9 · Cited by 24
Zachariah, P. J., Chen, C.-Y., Lee, W., Chen, S.-C., Ser, K., Chen, J., & Lee, Y.-C. (2016) · Obesity Surgery · doi:10.1007/s11695-016-2205-1 · Cited by 23
“Though we have not estimated gut hormones in this study, our premise was that these hormonal changes needed to have their final impact on the food intake anyway through appetite sensations [11, 35].”
BackgroundImpact of glucagon‐like peptide‐1 on endothelial function
Sjöholm, Å. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01074.x · Cited by 22
Saraceni, C., & Broderick, T. L. (2007) · Drugs in R&D · doi:10.2165/00126839-200708030-00002 · Cited by 25
Waters, S. B., Topp, B. G., Siler, S. Q., & Alexander, C. M. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300108 · Cited by 22
Murata, Y., Harada, N., Kishino, S., Iwasaki, K., Ikeguchi, E., Yamane, S., Kato, T., Kanemaru, Y., Sankoda, A., Hatoko, T., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102963 · Cited by 26
Incretin-Based Therapy and Type 2 Diabetes
Hare, K. J., & Knop, F. K. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00015-1 · Cited by 24
Glucagon-like peptide-1 secretion in bulimia nervosa
Brambilla, F., Monteleone, P., & Maj, M. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2008.06.040 · Cited by 22
“All these effects have been tentatively suggested, among other hypotheses, to underlie the increased feeling of satiety after feeding (Flint et al.,1998, 2001; Verdick et al., 2001; Vettor et al., 2002; De Graaf et al., 2004; Stanley et al., 2004; Meier and Nauck, 2005; Lopez et al., 2007).”
BackgroundHolst, J. J. (2002) · BioDrugs · doi:10.2165/00063030-200216030-00002 · Cited by 24
“This has been demonstrated in normal and obese individuals and in those with type 2 diabetes mellitus.[61-63] This effect supports attempts at weight reduction in patients with type 2 diabetes mellitus and, if effective, would be considered most desirable.”
BackgroundSelf-citationNäslund, E. B., Skogar, S., Efendić, S., & Hellström, P. M. (2002) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00054-x · Cited by 25
Importance of Orexigenic Counter‐Regulation for Multiple Targeted Feeding Inhibition
SCHUSDZIARRA, V., Zimmermann, J., & Schick, R. (2004) · Obesity Research · doi:10.1038/oby.2004.72 · Cited by 24
Hansen, E. N., Torquati, A., & Abumrad, N. N. (2006) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.26.061505.111242 · Cited by 26
Targeting skeletal muscle mitochondrial health in obesity
Pileggi, C. A., Hooks, B. G., McPherson, R., Dent, R. R. M., & Harper, M.-E. (2022) · Clinical Science · doi:10.1042/cs20210506 · Cited by 21
Incretin-based therapeutics for the treatment of neurodegenerative diseases
Vear, A., Heneka, M. T., & Clemmensen, C. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01263-4 · Cited by 26
“A few years later, intravenous infusion of GLP-1 was also shown to decrease appetite and food intake in humans 64 .”
Bernosky‐Smith, K. A., Stanger, D. B., Trujillo, A. J., Mitchell, L. R., España, R. A., & Bass, C. E. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.12.007 · Cited by 24
“EX4 is often prescribed off-label for the treatment of obesity due to its ability to decrease food intake and promote satiety (Flint et al., 1998).”
BackgroundMicroRNA-194: a novel regulator of glucagon-like peptide-1 synthesis in intestinal L cells
Wang, J., Zhao, D., Ding, C., Guo, F., Wu, L., Huang, F., Liu, Y., Zhao, S., Xin, Y., Ma, S., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03366-0 · Cited by 21
“This conclusion was supported by the following distinct observations: (1) a negative correlation existed between plasma GLP-1 level and ileac miR-194 expression in HFD-induced obese mice; (2) miR-194 overexpression reduced GLP-1 level in IL-6-treated STC-1 cells via repressing transcriptions of gcg and pcsk1; (3) miR-…”
ResultXie, C., Iroga, P. E., Bound, M. J., Grivell, J., Huang, W., Jones, K. L., Horowitz, M., Rayner, C. K., & Wu, T. (2024) · Diabetologia · doi:10.1007/s00125-024-06131-6 · Cited by 26
“GLP-1 modulates glucose homeostasis via pleiotropic actions [15, 16], including stimulation of insulin secretion, suppression of glucagon release [17], slowing of gastric emptying [18] and inhibition of appetite [19].”
BackgroundMechanisms and pharmacotherapy of cancer cachexia‐associated anorexia
Sato, R., da Fonseca, G. W. P., das Neves, W., & von Haehling, S. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70031 · Cited by 24
“65 GLP-1 analogs that mimic the action of this incretin hormone have been shown to pro - duce significant weight loss through mechanisms such as prolonging gastric emptying, 66 promoting satiety, 67 and increasing energy expen - diture by brown remodeling of white adipose tissue and lipolysis.”
Melhorn, S. J., Tyagi, V., Smeraglio, A., Roth, C. L., & Schur, E. A. (2014) · Appetite · doi:10.1016/j.appet.2014.07.009 · Cited by 21
“Several studies do show effects of exogenous GLP-1(Flint et al., 1998, Gutzwiller et al., 1999, Gutzwiller et al., 1999, Degen et al., 2006) or GLP-1 agonists (Edwards et al., 2001) on appetite in humans.”
BackgroundInfluentialRondanelli, M., Opizzi, A., Perna, S., Faliva, M. A., Solerte, S. B., Fioravanti, M., Klersy, C., Cava, E., Maddalena, P., Luciano, S., et al. (2013) · Journal of the American College of Nutrition · doi:10.1080/07315724.2013.767667 · Cited by 22
“It increases satiety and suppresses appetite in normal-weight subjects [59, 60], so we could hypothesize that a positive correlation exists between the increase in GLP-1 and the increased feeling of satiety in the supplemented group.”
BackgroundNew physiological effects of the incretin hormones GLP-1 and GIP.
Asmar, M. (2011) · PubMed · Cited by 29
G Protein-Coupled Receptors as Regulators of Energy Homeostasis
Tao, Y., Yuan, Z., & Xie, J. (2013) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-386933-3.00001-7 · Cited by 21
Molecular and Materials Engineering for Delivery of Peptide Drugs to Treat Type 2 Diabetes
Varanko, A. K., & Chilkoti, A. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801509 · Cited by 23
Juel, C. T., Lund, A., Andersen, M. M., Hansen, C. P., Storkholm, J. H., Rehfeld, J. F., van Hall, G., Hartmann, B., Albrechtsen, N. J. W., Holst, J. J., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05158-9 · Cited by 22
“Extrapancreatic effects of GLP-1 include decreased gastrointestinal motility [4], lowering of postprandial plasma triacylglycerol concentrations [5], promotion of satiety [6, 7, 8] and weight loss [8], lowering of systolic blood pressure and cardiovascular and kidney protective effects during chronic administration in…”
BackgroundSelf-citationRose, B. D., Bitarafan, V., Rezaie, P., Fitzgerald, P. C. E., Horowitz, M., & Feinle‐Bisset, C. (2021) · Journal of Nutrition · doi:10.1093/jn/nxab020 · Cited by 27
Pyruvate dehydrogenase as a therapeutic target for obesity cardiomyopathy
Lewis, A., Neubauer, S., Tyler, D. J., & Rider, O. J. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1126248 · Cited by 21
“[98] One further benefit of GLP-1 analogues is to promote satiety, thus reducing energy intake and leading to weight loss.[99] These data sug-”
BackgroundPhysiology, pathophysiology and therapeutic implications of enteroendocrine control of food intake
Elliott, J. A., Reynolds, J. V., le Roux, C. W., & Docherty, N. G. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1245140 · Cited by 22
Promising New Approaches to the Management of Obesity
Mertens, I. L., & Gaal, L. F. V. (2000) · Drugs · doi:10.2165/00003495-200060010-00001 · Cited by 24
“[29] Studies have shown that an intravenous infusion of GLP-1 also slows gastric emptying in obese men,[30] and reduces energy intake in lean[31] and obese men[32] and in male patients with type 2 diabetes.”
BackgroundExpression and purification of exendin-4, a GLP-1 receptor agonist, in Escherichia coli
Yin, X., Wei, D., Yi, L., Tao, X., & Ma, Y. (2005) · Protein Expression and Purification · doi:10.1016/j.pep.2004.10.014 · Cited by 21
Eating disorders: a role for dipeptidyl peptidase IV in nutritional control
Hildebrandt, M., Rose, M., Mönnikes, H., Reutter, W. G., Keller, W., & Klapp, B. F. (2001) · Nutrition · doi:10.1016/s0899-9007(01)00547-0 · Cited by 21
Differential responses of circulating amylin to high‐fat vs. high‐carbohydrate meal in healthy men
Eller, L. K., Ainslie, P. N., Poulin, M. J., & Reimer, R. A. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03129.x · Cited by 20
Jensen, S. B. K., Lundgren, J. R., Janus, C., Juhl, C. R., Olsen, L. M., Rosenkilde, M., Holst, J. J., Stallknecht, B. M., Madsbad, S., & Torekov, S. S. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-031431 · Cited by 20
“GLP-1 dosedependently stimulates glucosedependent insulin secretion thereby lowering blood glucose and reduces appetite and thereby food intake.(30) 31 32 33 Treatment for 56 weeks with the GLP-1 receptor agonist (GLP-1 RA), liraglutide (3.”
BackgroundSelf-citationEuglycemic diabetic ketoacidosis after the initiation of dulaglutide in patient with type 2 diabetes
Alduraibi, R. K., Alrebdi, Y. M., & Altowayan, Y. F. (2023) · Medicine · doi:10.1097/md.0000000000034027 · Cited by 21
“This relatively new group of drugs has the following effects: improved insulin release, slow gastric emptying and decrease appetite.[12] The American Diabetes Association also recommended that GLP1 receptor agonists should be one of the first combination drugs considered in the treatment of patients with type 2 diabet…”
BackgroundHormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease
Chui, Z. S. W., Xue, Y., & Xu, A. (2024) · Medical Review · doi:10.1515/mr-2024-0007 · Cited by 21
Teo, Y. Q. J., Chong, B., Soong, R. Y., Yong, C. L., Chew, N., & Chew, H. S. J. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.05.019 · Cited by 25
Scott, R., Tan, T., & Bloom, S. R. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-407766-9.00007-9 · Cited by 20
Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases?
Cornall, L. M., Mathai, M. L., Hryciw, D. H., & McAinch, A. J. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.775245 · Cited by 21
“It is also plausible that GLP-1 could again be important in modulating feeding behaviour, with GLP-1 being shown to decelerate gastrointestinal motility [41] and promote satiety [42], which may be increased in response to accrual of intestinal cell cAMP.”
BackgroundCirculating glucagon-like peptide-1 increases in response to short-term overfeeding in men
Wadden, D., Cahill, F., Amini, P., Randell, E. W., Vasdev, S., Yi, Y., Church, J. G., & Sun, G. (2013) · Nutrition & Metabolism · doi:10.1186/1743-7075-10-33 · Cited by 23
“Other effects include, decreased appetite [12-14] and decreased gastric motility and secretion [15,16].”
BackgroundDavidson, J. A., Parente, E. B., & Gross, J. L. (2008) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302008000600016 · Cited by 29
“GLP-1 is a multifunctional hormone which also inhibits glucagon secretion, slows gastric emptying and functions as a regulator of satiety (28-34).”
BackgroundIbarra, A., Olli, K., Pasman, W. J., Hendriks, H., Alhoniemi, E. J., Raza, G. S., Herzig, K., & Tiihonen, K. (2016) · Appetite · doi:10.1016/j.appet.2016.12.002 · Cited by 20
Hunger and thirst interact to regulate ingestive behavior in flies and mammals
Jourjine, N. (2017) · BioEssays · doi:10.1002/bies.201600261 · Cited by 25
Metadata
- Authors
- Flint, A., Raben, A., Astrup, A., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- Journal of Clinical Investigation
- Published
- 1998-02-01
- Volume
- 101
- Issue
- 3
- Pages
- 515-520
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC508592
- OpenAlex
- W1975756049
- Cited by
- 1,402
- References
- 40
- Citations by year
- 2026: 37 · 2025: 55 · 2024: 62 · 2023: 33 · 2022: 55 · 2021: 53 · 2020: 49 · 2019: 44 · 2018: 52 · 2017: 49 · 2016: 54 · 2015: 59 · 2014: 64 · 2013: 74 · 2012: 72
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Sundhed og Sygdom, Det Frie Forskningsråd
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucagon-like peptide-1, satiety, appetite, energy intake, insulin, glucagon, blood glucose, appetite regulation, intravenous infusion
- MeSH terms
- Adult, Appetite, Appetite Depressants, Appetite Regulation, Blood Glucose, Energy Intake, Glucagon, Humans, Insulin, Male, Pain Measurement, Peptide Fragments, Protein Precursors, Satiation, Cross-Over Studies, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.